FibroGen (FGEN) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free FGEN Stock Alerts $1.20 -0.04 (-3.23%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | americanbankingnews.comFibroGen, Inc. (NASDAQ:FGEN) Expected to Post Q2 2024 Earnings of ($0.24) Per ShareMay 10, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) to Post Q2 2024 Earnings of ($0.24) Per Share, William Blair ForecastsFibroGen, Inc. (NASDAQ:FGEN - Free Report) - Equities researchers at William Blair increased their Q2 2024 earnings estimates for shares of FibroGen in a research note issued on Tuesday, May 7th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.24) pMay 10, 2024 | americanbankingnews.comBrokers Issue Forecasts for FibroGen, Inc.'s Q1 2025 Earnings (NASDAQ:FGEN)May 9, 2024 | marketbeat.comFibroGen, Inc. to Post Q1 2025 Earnings of $0.00 Per Share, William Blair Forecasts (NASDAQ:FGEN)FibroGen, Inc. (NASDAQ:FGEN - Free Report) - Research analysts at William Blair cut their Q1 2025 earnings estimates for shares of FibroGen in a note issued to investors on Tuesday, May 7th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings per shareMay 8, 2024 | finance.yahoo.comFibroGen First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | msn.comFibroGen Shares Climb On Strong Q1 SalesMay 7, 2024 | finance.yahoo.comFibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call TranscriptMay 7, 2024 | markets.businessinsider.comGoldman Sachs Remains a Sell on FibroGen (FGEN)May 7, 2024 | finance.yahoo.comFibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 7, 2024 | globenewswire.comFibroGen to Participate in Upcoming Investor ConferencesMay 6, 2024 | msn.comFGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | finance.yahoo.comFibroGen Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comFibroGen Reports First Quarter 2024 Financial ResultsMay 5, 2024 | markets.businessinsider.comHere's what Wall Street expects from FibroGen's earningsMay 3, 2024 | msn.comFibroGen Q1 2024 Earnings PreviewApril 30, 2024 | marketbeat.comFibroGen (FGEN) Scheduled to Post Earnings on MondayFibroGen (NASDAQ:FGEN) will be releasing earnings after the market closes on Monday, May 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=590952)April 29, 2024 | globenewswire.comFibroGen to Report First Quarter 2024 Financial ResultsApril 24, 2024 | finance.yahoo.comFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual MeetingApril 24, 2024 | globenewswire.comFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual MeetingApril 17, 2024 | msn.comFibroGen (FGEN) Price Target Increased by 40.00% to 1.79April 16, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) Short Interest UpdateFibroGen, Inc. (NASDAQ:FGEN - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 5,190,000 shares, a decrease of 6.1% from the March 15th total of 5,530,000 shares. Approximately 5.7% of the shares of the stock are sold short. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is presently 1.9 days.April 4, 2024 | marketbeat.comAnalysts Set Expectations for FibroGen, Inc.'s Q1 2025 Earnings (NASDAQ:FGEN)FibroGen, Inc. (NASDAQ:FGEN - Free Report) - William Blair issued their Q1 2025 EPS estimates for FibroGen in a research note issued on Wednesday, April 3rd. William Blair analyst A. Hsieh forecasts that the biopharmaceutical company will post earnings per share of $0.04 for the quarter. WilliamApril 3, 2024 | markets.businessinsider.comFibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The LandscapeApril 3, 2024 | msn.comFibroGen falls after early-stage data for prostate cancer drugApril 3, 2024 | markets.businessinsider.comFibroGen (FGEN) Gets a Sell from Goldman SachsApril 2, 2024 | globenewswire.comFibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerMarch 26, 2024 | globenewswire.comFibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceMarch 20, 2024 | investorplace.com3 Nightmare Nasdaq Stocks Not Worth Holding Another DayMarch 12, 2024 | insidertrades.comInsider Buying: FibroGen, Inc. (NASDAQ:FGEN) CEO Buys 50,000 Shares of StockMarch 11, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) CEO Thane Wettig Buys 50,000 SharesFibroGen, Inc. (NASDAQ:FGEN - Get Free Report) CEO Thane Wettig bought 50,000 shares of the business's stock in a transaction dated Thursday, March 7th. The stock was acquired at an average price of $1.91 per share, for a total transaction of $95,500.00. Following the purchase, the chief executive officer now directly owns 470,178 shares in the company, valued at $898,039.98. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 11, 2024 | finanznachrichten.deFibroGen, Inc.: FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerMarch 11, 2024 | markets.businessinsider.comFibroGen Appoints Deyaa Adib As CMOMarch 11, 2024 | globenewswire.comFibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerMarch 3, 2024 | marketbeat.comArmistice Capital LLC Purchases 3,536,000 Shares of FibroGen, Inc. (NASDAQ:FGEN)Armistice Capital LLC grew its position in FibroGen, Inc. (NASDAQ:FGEN - Free Report) by 81.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,892,000 shares of the biopharmaceutical company's stock after acquiring an additFebruary 29, 2024 | marketbeat.comWilliam Blair Weighs in on FibroGen, Inc.'s Q2 2024 Earnings (NASDAQ:FGEN)FibroGen, Inc. (NASDAQ:FGEN - Free Report) - Research analysts at William Blair raised their Q2 2024 earnings estimates for shares of FibroGen in a note issued to investors on Tuesday, February 27th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earningsFebruary 29, 2024 | finance.yahoo.comUS$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest ResultsFebruary 29, 2024 | finance.yahoo.comFibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comFibroGen Full Year 2023 Earnings: Misses ExpectationsFebruary 28, 2024 | marketbeat.comAcadian Asset Management LLC Purchases Shares of 1,615,094 FibroGen, Inc. (NASDAQ:FGEN)Acadian Asset Management LLC purchased a new stake in shares of FibroGen, Inc. (NASDAQ:FGEN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,615,094 shares of the biophaFebruary 27, 2024 | finanznachrichten.deFibroGen, Inc.: FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | marketbeat.comFibroGen (NASDAQ:FGEN) Rating Reiterated by William BlairWilliam Blair restated a "market perform" rating on shares of FibroGen in a report on Tuesday.February 26, 2024 | finance.yahoo.comFibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023February 26, 2024 | reuters.comFibroGen regains rights to anemia drug from AstraZenecaFebruary 26, 2024 | globenewswire.comFibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | globenewswire.comFibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaFebruary 26, 2024 | marketbeat.comPrimecap Management Co. CA Has $12.71 Million Stake in FibroGen, Inc. (NASDAQ:FGEN)Primecap Management Co. CA increased its holdings in FibroGen, Inc. (NASDAQ:FGEN - Free Report) by 7.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,724,968 shares of the biopharmaceutical company's sFebruary 25, 2024 | markets.businessinsider.comHere's what Wall Street expects from FibroGen's earnings reportFebruary 24, 2024 | finance.yahoo.comFGEN Jan 2026 1.000 callFebruary 23, 2024 | benzinga.comFibroGen's Earnings OutlookFebruary 21, 2024 | benzinga.comFibroGen Stock (NASDAQ:FGEN) Insider Trades Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide FGEN Media Mentions By Week FGEN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FGEN News Sentiment▼0.250.42▲Average Medical News Sentiment FGEN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FGEN Articles This Week▼03▲FGEN Articles Average Week Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Syros Pharmaceuticals News Today Sagimet Biosciences News Today PDS Biotechnology News Today Amylyx Pharmaceuticals News Today DiaMedica Therapeutics News Today Repare Therapeutics News Today Nuvectis Pharma News Today Adicet Bio News Today Karyopharm Therapeutics News Today Regulus Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FGEN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
